A039860 Stock Overview
Engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
NanoEntek, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,990.00 |
52 Week High | ₩5,810.00 |
52 Week Low | ₩2,705.00 |
Beta | 0.71 |
11 Month Change | 25.08% |
3 Month Change | 43.27% |
1 Year Change | 14.99% |
33 Year Change | -45.19% |
5 Year Change | -15.91% |
Change since IPO | -11.14% |
Recent News & Updates
Revenues Not Telling The Story For NanoEntek, Inc. (KOSDAQ:039860) After Shares Rise 32%
Oct 10NanoEntek, Inc.'s (KOSDAQ:039860) Revenues Are Not Doing Enough For Some Investors
Aug 06Recent updates
Revenues Not Telling The Story For NanoEntek, Inc. (KOSDAQ:039860) After Shares Rise 32%
Oct 10NanoEntek, Inc.'s (KOSDAQ:039860) Revenues Are Not Doing Enough For Some Investors
Aug 06NanoEntek, Inc.'s (KOSDAQ:039860) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Mar 21Should Weakness in NanoenTek, Inc.'s (KOSDAQ:039860) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 14If You Had Bought NanoEnTek (KOSDAQ:039860) Shares A Year Ago You'd Have Earned 48% Returns
Jan 26Calculating The Intrinsic Value Of NanoEnTek, Inc. (KOSDAQ:039860)
Jan 04NanoEnTek Inc.'s (KOSDAQ:039860) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 14Does NanoEnTek's (KOSDAQ:039860) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Shareholder Returns
A039860 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | -6.2% | -5.9% | -1.2% |
1Y | 15.0% | 46.4% | 4.8% |
Return vs Industry: A039860 underperformed the KR Life Sciences industry which returned 46.4% over the past year.
Return vs Market: A039860 exceeded the KR Market which returned 4.8% over the past year.
Price Volatility
A039860 volatility | |
---|---|
A039860 Average Weekly Movement | 17.0% |
Life Sciences Industry Average Movement | 10.3% |
Market Average Movement | 6.7% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A039860's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A039860's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 275 | Jin-Hyung Park | www.nanoentek.com |
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company was founded in 1987 and is headquartered in Seoul, South Korea.
NanoEntek, Inc. Fundamentals Summary
A039860 fundamental statistics | |
---|---|
Market cap | ₩128.12b |
Earnings (TTM) | -₩473.12m |
Revenue (TTM) | ₩27.80b |
4.6x
P/S Ratio-270.8x
P/E RatioIs A039860 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A039860 income statement (TTM) | |
---|---|
Revenue | ₩27.80b |
Cost of Revenue | ₩14.26b |
Gross Profit | ₩13.54b |
Other Expenses | ₩14.02b |
Earnings | -₩473.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -14.73 |
Gross Margin | 48.71% |
Net Profit Margin | -1.70% |
Debt/Equity Ratio | 0% |
How did A039860 perform over the long term?
See historical performance and comparison